SCHEDULE: Woodline Partners Discloses 6.2% Stake in Zevra Therapeutics
Beneficial Ownership Report (Schedule 13G)
Woodline Partners LP has reported a 6.2% beneficial ownership stake in Zevra Therapeutics, Inc., holding 3,476,143 shares of common stock.
Summary
- Woodline Partners LP, an investment adviser, has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Zevra Therapeutics, Inc.
- Woodline Partners LP beneficially owns 3,476,143 shares of Zevra Therapeutics' common stock.
- This ownership represents 6.2% of the company's outstanding common stock.
- The percentage calculation is based on 56,135,091 shares of common stock outstanding as of August 8, 2025, as reported in Zevra Therapeutics' Form 10-Q for the quarter ended June 30, 2025.
- Woodline Partners LP holds sole voting power and sole dispositive power over all 3,476,143 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant 6.2% stake by an investment adviser like Woodline Partners LP is generally viewed as a positive signal of institutional confidence in the company's prospects, even if the investment is passive. No negative information is presented.
Positives
- A significant institutional investor, Woodline Partners LP, holds a 6.2% stake, indicating confidence in Zevra Therapeutics' prospects.
Future Outlook
The filing does not provide any forward-looking statements or guidance from Zevra Therapeutics or Woodline Partners LP regarding the company's future performance or strategic direction.
Industry Context
Schedule 13G filings are standard disclosures by institutional investors who acquire more than 5% of a company's voting class of securities, indicating a passive investment intent. The disclosure of Woodline Partners LP's stake in Zevra Therapeutics signals an institutional investor's interest in the company, which can be viewed positively by the market.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially attract further institutional interest, potentially supporting the stock price.
- Company Management: Awareness of a significant passive institutional holder may influence management's focus on shareholder value, though Woodline Partners has certified a passive intent.
Key Dates
| Date | Description |
|---|---|
| 2025-08-08 | Date as of which 56,135,091 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-08-12 | Date Zevra Therapeutics filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-14 | Date of signing the Schedule 13G Amendment No. 1. |
Keywords
Zevra Therapeutics, Woodline Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, 488445206
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.